BridgeBio Presents Results of Encaleret in P-IIb Study for the Treatment of ADH1 at ENDO 2021

Shots:

• The ongoing P-IIb POC, open-label study involves assessing Encaleret (starting dose: 30 mg) in 6 patients for the treatment of ADH1
• The results showed normalization of blood calcium and urine calcium, well-tolerated and consistent mineral responses with no serious AEs, and no AEs of moderate or severe intensity reported after 5 days, at doses up to 180 mg
• Encaleret could be the 1^st approved therapy option indicated specifically for the treatment of ADH1, if the development program is successful

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire